Positive high-level results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, showed consistency to those in the global BridgeBio Pharma (BBIO) ATTRibute-CM Phase III trial, including survival, cardiac-related hospitalisations and other measures of improved functions and quality of life at 30 months, reported AstraZeneca (AZN). This trial in Japan was conducted to support local registration. Alexion, AstraZeneca Rare Disease, maintains an exclusive licence with BridgeBio’s affiliate, Eidos Therapeutics, Inc. to develop and commercialise acoramidis in Japan. The success criterion in the open-label Phase III trial in Japan was defined as greater estimated survival probability at 30 months than that observed among placebo patients in ATTRibute-CM.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca call volume above normal and directionally bullish
- Unusually active option classes on open January 30th
- FDA grants AstraZeneca’s ENHERTU priority review for HER2-directed treatment
- FDA grants AstraZeneca’s ENHERTUpriorityreview for HER2-directed treatment
- AstraZeneca, Daiichi Sankyo announce sBLA for Enhertu granted priority review